|
Treatment-related observational studies
|
|
Driessen 2008[68]
|
PASI
|
-
|
-
|
|
Fortune 2003[6]
|
Time taken to achieve clearance of psoriasis
|
Psychological distress, alcohol intake, HADS
|
-
|
|
Lecha 2005[70]
|
psoriasis severity and area, global efficacy and tolerability
|
Patients' satisfaction [tools not described].
|
-
|
|
Naldi 2008[71]
|
PASI, BMI
|
-
|
-
|
|
Paul 2003[72]
|
Malignancies
|
-
|
-
|
|
Wahl 2005[73]
|
SPASI
|
SF-36, one item on QOL and one assessment of self-acceptance
|
-
|
|
Heiberg 2008[74]
|
DAS-28
|
HAQ; SF-36; SF-6D (utility)
|
-
|
|
Kristensen 2008[76]
|
DAS-28, erythrocyte sedimentation rate and C-reactive protein
|
EQ-5D (utility) HAQ, VAS-pain, VAS-global, global evaluation
|
-
|
|
Sparado 1997[80]
|
Type of therapy; drug continuation; Number of painful and swollen joints; remission
|
-
|
-
|
|
Saad 2009[81]
|
Drug persistence; DAS-28
|
HAQ adapted for UK use and SF-36
|
-
|
|
Non-treatment related observational studies
|
|
Carrascosa 2006[84]
|
PASI
| |
Direct, indirect
|
|
Colombo 2008[11]
|
PASI
|
SF-36, DLQI
|
Direct, indirect
|
|
Schmid-ott 2005[85]
|
PASI, SPASI
|
QES
|
-
|
|
Husted 2007[2]
|
Mortality; PASI; Duration of morning stiffness, and total numbers of actively inflamed joints; incidence of CVD; malignancies
|
HAQ
|
-
|
|
Kane 2003[95]
|
PASI, Ritchie Articular Index, EULAR swollen joint count, joint stiffness on waking.
|
HAQ
|
-
|
|
Lindqvist 2008[97]
|
66/68 joint counts, PASI, physician's global assessment of joint disease activity, and subclassification; remission
|
VAS, HAQ, SF-36
|
-
|
